DEFENSIN THERAPEUTICS ApS: Financial statements 2021
CVR: 35513280
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
DEFENSIN THERAPEUTICS ApS (CVR 35513280) has filed annual accounts for 2021. In 2021, the company reported a net result of DKK -365,611 compared with DKK -2,315,678 the year before. Equity in the 2021 report amounted to DKK 2,141,889. The solvency ratio was 98.3%.
- Revenue
- DKK 0
- Profit/Loss
- DKK -365,611
- Equity
- DKK 2,141,889
- Total Assets
- DKK 2,179,687
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | 0 | - | -366K | 2.1M | - |
| 2020 | - | - | -2.3M | 2.5M | 0 |
| 2019 | - | - | -1.7M | 4.8M | 1 |
| 2018 | - | - | -3M | 1M | - |
| 2017 | 0 | 0 | -2M | 3.9M | - |
Official annual report
Find more companies like DEFENSIN THERAPEUTICS ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2021
DEFENSIN THERAPEUTICS ApS has published its annual report for 2020. The net result was DKK -2,315,678.
About DEFENSIN THERAPEUTICS ApS
DEFENSIN THERAPEUTICS ApS is a Danish company of the type Anpartsselskab based in København K, founded in 2013. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Peter Hviid Nordkild. The board consists of Ejner Bech Jensen (chair), Matthew Alister Cooper, Peter Hviid Nordkild and Robert Ehehalt. The company's owners include NOVOZYMES A/S, PN INVESTMENT ApS and NEVE INVEST ApS. The company has 0 employees (2018). In 2025, the company reported a gross profit of DKK -538,913 and a net result of DKK -539,063 compared with DKK -130,534 the year before. Equity in the 2025 report amounted to DKK 774,437.